[Abstract] [Full Text HTML] [Full Text PDF] (in Japanese / 421KB) [Members Only]

J.Jpn. Surg. Soc.. 118(6): 610-615, 2017

Feature topic


1) Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
2) Department of Breast, Thyroid and Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan

Hisato Hara1), Kawamura Chitose2), Saori Fujiwara2), Yukari Ando2), Tomohei Matsuo2), Rio Takagi2), Aoi Hoshi2), Keita Sasaki2), Aya Sawa2), Sachie Hashimoto2), Azusa Terasaki2), Mai Okazaki2), Kana Tachi2), Emika Ichioka2), Yukiko Tsushima1), Akiko Iguchi1), Hiroko Bando1)

Since 2014, the administration of tyrosine-kinase inhibitors (TKIs) has become a new line of therapy for thyroid carcinoma that does not respond to any other chemotherapy regimen. The indications for TKI treatment in differentiated thyroid carcinoma, which comprises most cases of thyroid carcinoma, are limited to radioactive iodine-refractory and/or unresectable lesions showing rapid progression. Recently, therapies using TKIs for unresectable anaplastic thyroid carcinoma and unresectable medullary thyroid carcinoma have also become available. However, TKIs are often associated with severe adverse events and affect patient quality of life. Therefore, TKIs should be administered only when thyroid carcinoma cannot be controlled by other agents after carefully considering the therapeutic risks and benefits.
At present, the first choice of therapy for any type of thyroid carcinoma is surgical management. TKIs are not a replacement for surgery, and surgeons should attempt the previously established resection procedures. In addition, preoperative treatment and postoperative adjuvant therapy with TKIs have not yet been established. Although the results of future clinical studies are awaited, TKIs are not currently recommended as preoperative or postoperative adjuvant treatment in thyroid carcinoma.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.